Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

NCT01345734 · Completed

Last updated 2026-05-28

This study observes the safety of the diabetes medication liraglutide in adults with type 2 diabetes by tracking serious side effects.

Status Completed The study has finished.

Type Observational

Participants 1,056 people

Who can join all sexes

Timeline Started 2011-09 · est. completion 2013-07

Where 1 site · Philippines

What this study is testing ClinicalTrials.gov NCT01345734 ↗

Description as written by the study sponsor.

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

liraglutide Drug

Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.

Main thing measured	Incidence of serious adverse drug reactions (SADRs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01345734 ↗